These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 16497559

  • 1. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice.
    Su C, Peng L, Sham J, Wang X, Zhang Q, Chua D, Liu C, Cui Z, Xue H, Wu H, Yang Q, Zhang B, Liu X, Wu M, Qian Q.
    Mol Ther; 2006 May; 13(5):918-27. PubMed ID: 16497559
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Telomerase-dependent oncolytic adenovirus for cancer treatment.
    Huang TG, Savontaus MJ, Shinozaki K, Sauter BV, Woo SL.
    Gene Ther; 2003 Aug; 10(15):1241-7. PubMed ID: 12858189
    [Abstract] [Full Text] [Related]

  • 4. Potent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mEndostatin in hepatocellular carcinoma.
    Li GC, Yang JM, Nie MM, Su CG, Sun LC, Qian YZ, Fang GE, Sham J, Wu MC, Qian QJ.
    Chin Med J (Engl); 2005 Feb 05; 118(3):179-85. PubMed ID: 15740644
    [Abstract] [Full Text] [Related]

  • 5. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene.
    Zhang Q, Nie M, Sham J, Su C, Xue H, Chua D, Wang W, Cui Z, Liu Y, Liu C, Jiang M, Fang G, Liu X, Wu M, Qian Q.
    Cancer Res; 2004 Aug 01; 64(15):5390-7. PubMed ID: 15289347
    [Abstract] [Full Text] [Related]

  • 6. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS.
    Cancer Gene Ther; 2004 Mar 01; 11(3):174-85. PubMed ID: 14726958
    [Abstract] [Full Text] [Related]

  • 7. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, Lu ZZ, Wang LS.
    Cancer Gene Ther; 2008 Mar 01; 15(3):173-82. PubMed ID: 18157145
    [Abstract] [Full Text] [Related]

  • 8. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
    Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS, Toth K.
    Gene Ther; 2005 Nov 01; 12(22):1608-17. PubMed ID: 16034456
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy.
    Su C, Na M, Chen J, Wang X, Liu Y, Wang W, Zhang Q, Li L, Long J, Liu X, Wu M, Fan X, Qian Q.
    Mol Cancer Res; 2008 Apr 01; 6(4):568-75. PubMed ID: 18344493
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent.
    Zou W, Luo C, Zhang Z, Liu J, Gu J, Pei Z, Qian C, Liu X.
    Oncogene; 2004 Jan 15; 23(2):457-64. PubMed ID: 14724574
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C, Liu X.
    J Gene Med; 2006 Oct 15; 8(10):1232-42. PubMed ID: 16900558
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H, Wei F, Li H, Ji X, Li S, Chen X.
    Int J Mol Med; 2013 Feb 15; 31(2):377-85. PubMed ID: 23229955
    [Abstract] [Full Text] [Related]

  • 18. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, Kim H, Cho S, Sohn JH, Kim GE, Yun CO.
    Gene Ther; 2006 Jul 15; 13(13):1010-20. PubMed ID: 16525479
    [Abstract] [Full Text] [Related]

  • 19. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo.
    Rivera AA, Wang M, Suzuki K, Uil TG, Krasnykh V, Curiel DT, Nettelbeck DM.
    Virology; 2004 Mar 01; 320(1):121-34. PubMed ID: 15003868
    [Abstract] [Full Text] [Related]

  • 20. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.
    Li Y, Idamakanti N, Arroyo T, Thorne S, Reid T, Nichols S, VanRoey M, Colbern G, Nguyen N, Tam O, Working P, Yu DC.
    Clin Cancer Res; 2005 Dec 15; 11(24 Pt 1):8845-55. PubMed ID: 16361574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.